OJBD  Vol.5 No.1 , March 2015
The Efficacy and Safety of a 1.6 mg/m2 Increase in a Bortezomib Regimen
ABSTRACT
We conducted a single-center, prospective clinical trial in which a subcutaneous bortezomib (Bor) regimen [1.6 mg/m2 per month (BD 1.6 mg/m2 therapy)] was administered to 22 multiple myeloma patients. All patients had been treated sufficiently with once-monthly subcutaneous Bor injections (BD 1.3 mg/m2therapy). Of the 22 patients, 13 had IgG-, 2 had IgA-, and 7 had Bence-Jones protein (BJP)-type multiple myeloma. The observation period for therapeutic effect determination ranged from 84 to 412 days (median: 400 days). Therapeutic effects were investigated in 15 patients during the increase in Bor from 1.3 to 1.6 mg/m2, and none achieved complete remission (CR), very good partial remission (VGPR), or partial remission (PR). Given the small number of patients, a significant conclusion must be reached carefully. However, the chance of stronger success with increases in Bor is low for patients who have already undergone long-term 1.3 mg/m2 Bor treatment. Furthermore, non-hematological toxicity was seen in 12 of 22 patients, so increasing Bor to 1.6 mg/m2 should be considered carefully. However, the statuses of patients in this study suggest that once-monthly Bor could inhibit disease progression. In future we should investigate low-frequency Bor maintenance therapy.

Cite this paper
Meshitsuka, S. and Suzuki, K. (2015) The Efficacy and Safety of a 1.6 mg/m2 Increase in a Bortezomib Regimen. Open Journal of Blood Diseases, 5, 1-8. doi: 10.4236/ojbd.2015.51001.
References
[1]   Aghajanian, C., Soignet, S., Dizon, D., Pien, C., Adams, J., Elliott, P., et al. (2002) A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies. Clinical Cancer Research, 8, 2505-2511.

[2]   Orlowski, R., Mitchell, B., Shea, T., Baldwin, A., Stahl, S., Adams, J., et al. (2002) Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Refractory Hematologic Malignancies. Journal of Clinical Oncology, 20, 4420-4427.
http://dx.doi.org/10.1200/JCO.2002.01.133

[3]   Papandreou, C., Daliani, D., Nix, D., Yang, H., Madden, T., Wang, X., et al. (2004) Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients with Advanced Solid Tumors with Observations in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 22, 2108-2121.
http://dx.doi.org/10.1200/JCO.2004.02.106

[4]   Hainsworth, J., Spigel, D., Barton, J., Farley, C., Schreeder, M., Hon, J., et al. (2008) Weekly Treatment with Bortezomib for Patients with Recurrent or Refractory Multiple Myeloma. Cancer, 113, 765-771.
http://dx.doi.org/10.1002/cncr.23606

[5]   Craig, B., Reeder, C., Reece, D., Kukreti, V., Chen, C., Trudel, S., et al. (2010) Once-versus Twice-Weekly Bortezomib Induction Therapy with CyBorD in Newly Diagnosed Multiple Myeloma. Blood, 115, 3416-3417.
http://dx.doi.org/10.1182/blood-2010-02-271676

[6]   Wang, Y., Ai, L., Cui, G., Gowrea, B., Li, M. and Hu, Y. (2012) Once-versus Twice-Weekly Bortezomib Induction Therapy with Dexamethasone in Newly Diagnosed Multiple Myeloma. Journal of Huazhong University of Science and Technology, 32, 495-500.
http://dx.doi.org/10.1007/s11596-012-0086-7

[7]   Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., et al. (2011) Subcutaneous versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma. The Lancet Oncology, 12, 431-440.
http://dx.doi.org/10.1016/S1470-2045(11)70081-X

[8]   Moreau, P., Coiteux, V., Hulin, C., Leleu, X., Velde, H., Acharya, M., et al. (2008) Prospective Comparison of Subcutaneous versus Intravenous Administration of Bortezomib in Patients with Multiple Myeloma. Haematologica, 93, 1908-1991.
http://dx.doi.org/10.3324/haematol.13285

[9]   Moreau, P., Karamanesht, I., Domnikova, N., Kyselyova, M., Vilchevska, K., Doronin, V., et al. (2012) Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma. Clinical Pharmacokinetics, 51, 823-829.
http://dx.doi.org/10.1007/s40262-012-0010-0

 
 
Top